Clinical Trial Update: A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating cobimetinib combinations with paclitaxel, atezolizumab-based regimens for metastatic triple-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-11-13